Gilead wins US approval for Yeztugo HIV prevention shot, but its $28,000 price sparks access concerns despite near-perfect ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 1 ...

Gilead Sciences, Inc. (NASDAQ:GILD) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Gilead Sciences, Inc.

The global HIV antivirals market is set for a period of robust growth, with a new forecast predicting its value will climb from an estimated USD 34.8 billion in 2025 to USD 53.6 billion by 2035. This ...

Patients with HIV who are resistant to all four antiretroviral drug classes face a higher risk for death than those who are ...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the most undervalued quality stocks to buy according to hedge funds. On July 25, the European Medicines Agency’s Committee for Medicinal Products for Human ...

The S&P 500 climbed Friday as tech stocks rallied, nearing its all-time closing high. Key Takeaways. The S&P 500 added 0.8% ...

Analysts lift targets for Gilead as HIV sales surge and Yeztugo launch gains traction, supporting a stronger full-year ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

Gilead Sciences ( NASDAQ: GILD) was upgraded to Buy from Hold at Truist after the company raised full year sales and profit ...